Literature DB >> 21088254

Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability.

Ailine Stolz1, Norman Ertych, Holger Bastians.   

Abstract

CHK2 is a multiorgan tumor susceptibility gene that encodes for a serine/threonine protein kinase involved in the response to cellular DNA damage. After ATM-mediated phosphorylation, the activated Chk2 kinase can act as a signal transducer and phosphorylate a variety of substrates, including the Cdc25 phosphatases, p53, PML, E2F-1, and Brca1, which has been associated with halting the cell cycle, the initiation of DNA repair, and the induction of apoptosis after DNA damage. In addition, recent work has revealed another, DNA-damage-independent function of Chk2 during mitosis that is required for proper mitotic spindle assembly and maintenance of chromosomal stability. This novel role involves a mitotic phosphorylation of the tumor suppressor Brca1 by the Chk2 kinase. On the basis of its role during DNA damage response, Chk2 has been suggested as an anticancer therapy target, but given its recently discovered new function and its role as a tumor suppressor, it is questionable whether inhibition of Chk2 is indeed beneficial for anticancer treatment. However, investigators may be able to exploit the loss of CHK2 in human tumors to develop novel therapies based on synthetic lethal interactions. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088254     DOI: 10.1158/1078-0432.CCR-10-1215

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

1.  Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.

Authors:  Elizabeth A Mazzio; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 4.069

2.  Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.

Authors:  Norman Ertych; Ailine Stolz; Albrecht Stenzinger; Wilko Weichert; Silke Kaulfuß; Peter Burfeind; Achim Aigner; Linda Wordeman; Holger Bastians
Journal:  Nat Cell Biol       Date:  2014-06-29       Impact factor: 28.824

3.  Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.

Authors:  Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Adam Conley; David E Durrant; Anindita Das; Paul B Fisher; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Mol Pharmacol       Date:  2013-12-18       Impact factor: 4.436

Review 4.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.

Authors:  Thomas P Matthews; Alan M Jones; Ian Collins
Journal:  Expert Opin Drug Discov       Date:  2013-04-18       Impact factor: 6.098

5.  Zinc finger protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage.

Authors:  Ruozhen Hu; Edward Wang; Guang Peng; Hui Dai; Shiaw-Yih Lin
Journal:  Cell Cycle       Date:  2013-06-06       Impact factor: 4.534

6.  The TIA1 RNA-Binding Protein Family Regulates EIF2AK2-Mediated Stress Response and Cell Cycle Progression.

Authors:  Cindy Meyer; Aitor Garzia; Michael Mazzola; Stefanie Gerstberger; Henrik Molina; Thomas Tuschl
Journal:  Mol Cell       Date:  2018-02-15       Impact factor: 17.970

7.  [Cell Cycle Checkpoint Kinase and Drug Resistance of Lung Cancer].

Authors:  Zhiyin Ke; Ailing Liang; Yongjun Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20

8.  The co-repressor SMRT delays DNA damage-induced caspase activation by repressing pro-apoptotic genes and modulating the dynamics of checkpoint kinase 2 activation.

Authors:  Claudio Scafoglio; Marcus Smolka; Huilin Zhou; Valentina Perissi; Michael G Rosenfeld
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.

Authors:  Mirta M L Sousa; Kamila Anna Zub; Per Arne Aas; Audun Hanssen-Bauer; Aida Demirovic; Antonio Sarno; Erming Tian; Nina B Liabakk; Geir Slupphaug
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.

Authors:  Da-Liang Ou; Bin-Shyun Lee; Ya-Chi Chang; Liang-In Lin; Jun-Yang Liou; Chiun Hsu; Ann-Lii Cheng
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.